In the journals: RSV vaccine during pregnancy and risk of preterm birth

Press Release

The VEC recently published an article discussing the results of trials of two RSV vaccines for pregnant people. On March 14, 2024, GSK published the results of its RSV trial in pregnant people (Dieussaert I, Kim JH, Luik S, et al. RSV prefusion F protein-based maternal vaccine—preterm birth and other outcomes. N Engl J Med. 2024 Mar 14;390(11):1009-1021).

For every 54 infants born to people who received vaccine rather than placebo during pregnancy, one additional preterm birth occurred. Due to this finding, the trial was stopped prematurely. It remains unclear why the GSK vaccine, but not the recently licensed Pfizer vaccine, was associated with preterm births. Check out the article in the Vaccine Update for Healthcare Providers and be sure to subscribe to keep up to date.

© 2024 MJH Life Sciences

All rights reserved.